Table 3.
Ongoing NET trials with PRRT.
| NCT | Protocol/Trial ID | Trial Title | Trial Phase |
|---|---|---|---|
| NCT03972488 | NETTER-2 | A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of lutathera in patients with grade 2 and grade 3 advanced GEP-NET | III |
| NCT02743741 | NA | Lu-DOTATATE treatment in patients with 68Ga-DOTATATE somatostatin receptor positive neuroendocrine tumors | NA |
| NCT05153772 | ALPHAMEDIX02 | Targeted alpha-emitter therapy of PRRT naive neuroendocrine tumor patients | II |
| NCT03773133 | NA | Evaluate the safety, tolerability, biodistribution and anti tumour activity of 177Lu-OPS201 with companion imaging 68Ga-OPS202 PET/CT in previously treated subjects with locally advanced or metastatic cancers expressing somatostatin receptor 2 (SSTR2) (SSTR2+) | II |
| NCT03457948 | NA | Pembrolizumab with liver-directed or peptide receptor radionuclide therapy for neuroendocrine tumors and liver metastases | II |
| NCT02489604 | LUNET | Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in advanced gastro-entero-pancreatic neuroendocrine tumors | II |
| NCT03454763 | LUTHREE | Optimizing the interval between cycles of PRRT with 177Lu-DOTATATE in SSTR2 positive tumors | II |
| NCT04525638 | NA | A clinical study to assess the combination of two drugs (177Lu-DOTATATE and Nivolumab) in neuroendocrine tumours | II |
| NCT02736448 | Lu-Ca-S | 177Lutethium - Peptide receptor radionuclide therapy (Lu-PRRT) plus Capecitabine versus Lu-PRRT in FDG positive, Gastro-entero-pancreatic neuroendocrine tumors | II |
| NCT04543955 | NA | Telotristat with Lutathera in neuroendocrine tumors | II |
| NCT03466216 | NA | Phase 1 study of alphamedix™ in adult subjects with SSTR (+) NET | I |
| NCT04234568 | NA | Testing the addition of an anti-cancer drug, triapine, to the usual radiation-based treatment (Lutetium Lu-177 DOTATATE) for neuroendocrine tumors | I |
| NCT04086485 | NA | Lu-177-DOTATATE (Lutathera) in combination with Olaparib in inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NET) | I |
| NCT04750954 | NA | Testing the addition of an anti-cancer drug, m3814 (Peposertib), to the usual radiation-based treatment (Lutetium Lu-177 DOTATATE) for neuroendocrine tumors | I |
NA, not applicable.